The paper explores how selectively blocking sFasL with our innovative monoclonal antibody PC111 could potentially transform the treatment landscape for diseases like severe drug reactions (DRESS/DIHS), autoimmune disorders (SLE, RA, Sjogren’s syndrome), and even acute respiratory distress syndrome (ARDS).
This effect adds up to what the PinCell team has shown in pemphigus vulgaris (PV) and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), where preclinical data demonstrates how it effectively blocks elevated sFasL, preventing blister formation in PV models and reducing apoptosis in SJS/TEN ones, with potential for rapid, non-immunosuppressive intervention.
In the above conditions:
sFasL drives pathogenesis by promoting inflammation, apoptosis in barrier cells (e.g., keratinocytes, epithelial cells) and tissue damage, without interfering with immune surveillance when it is selectively targeted.
Elevated sFasL levels correlate with disease severity, potentially positioning it as both a biomarker and druggable target.
Read the full article: https://www.tandfonline.com/doi/full/10.1080/09546634.2026.2635884